← Leaderboards
William James Waldman
Ohio State University
$2,683,316
Attributed
$2,683,316
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $307.6K · FY2008–11$500K$375K$250K$125K$0
'08
'09
'10
'11
Funding mix
By agency
NIH$2,683,316 · 4
By mechanism
R01$1,659,342 · 2
R56$607,649 · 1
R21$416,325 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Flavia Pichiorri$3,617,059
- Stefan Niewiesk$7,548,978
- Michael J Oglesbee$8,001,313
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusPhosphorylationVirus ProteinTransplantationTransmission Electron MicroscopyAntiviral AgentsPlaque AssayVirionGene ExpressionWestern BlottingsMolecular DynamicsInvestigationLungMedical ComplicationLaboratory RatOpportunistic InfectionsImmunosuppressiveAffectImmunoprecipitationImmunosuppressive AgentsImmunosuppressionBaseInjuryFlow Cytometry
Grant awards (10)
Endothelial-reactive antibodies: a diagnostic test for Susac's syndrome$149,450
R21 · FY2011 · NS · contact PI
Endothelial-reactive antibodies: a diagnostic test for Susac's syndrome$266,875
R21 · FY2010 · NS · contact PI
Antiviral activity of leflunomide against respiratory syncytial virus$300,000
R56 · FY2009 · AI · contact PI
Antiviral activity of leflunomide against respiratory syncytial virus$307,649
R56 · FY2008 · AI · contact PI
ANTIVIRAL ACTIVITY OF THE IMMUNOSUPPRESSANT LEFLUNOMIDE$283,230
R01 · FY2004 · AI
CMV DISRUPTION OF CONSTITUTIVE MHC CLASS II$258,125
R01 · FY2004 · AI
ANTIVIRAL ACTIVITY OF THE IMMUNOSUPPRESSANT LEFLUNOMIDE$283,230
R01 · FY2003 · AI
CMV DISRUPTION OF CONSTITUTIVE MHC CLASS II$262,550
R01 · FY2003 · AI
ANTIVIRAL ACTIVITY OF THE IMMUNOSUPPRESSANT LEFLUNOMIDE$280,660
R01 · FY2002 · AI
ANTIVIRAL ACTIVITY OF THE IMMUNOSUPPRESSANT LEFLUNOMIDE$291,547
R01 · FY2001 · AI